Alnylam: Q2 Earnings Snapshot
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $276 million in its second quarter.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.21.
The results fell short of Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of $1.72 per share.
The RNA interference drug developer posted revenue of $318.8 million in the period, also falling short of Street forecasts. Eight analysts surveyed by Zacks expected $331.7 million.
Alnylam shares have declined 21% since the beginning of the year. The stock has increased 32% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY
